| Ytd | -1.80% | |
| 1y | -47.08% |
| Open | 3.80 | Prev Close | 3.86 | Low | 3.80 | High | 3.86 | Mkt Cap | 20.59M |
| Vol | 4.06K | Avg Vol | 200.68K | EPS | -11.06 | P/E | -0.34 | Forward P/E | N/A |
| Beta | 0.75 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-17 | 50-d Avg | 4.05 | 200-d Avg | 4.36 | 1yr Est | 0.00 |
NEUP News
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, I
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Neuphoria Therapeutics
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge
NEW YORK, July 24, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Ass
Gainers NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regula
Scancell Holdings plc (AIM: SCLP) ("Scancell") and Neuphoria Therapeutics Inc. (NASDAQ:NEUP)
OXFORD, United Kingdom and BURLINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings pl
Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combinati
Major M&A deals this week include: LVMH agrees to sell Marc Jacobs to WHP Global, 365 Markets bu
Immunic (NASDAQ: IMUX - Get Free Report) and Neuphoria Therapeutics (NASDAQ: NEUP - Get Free Report)
Prenetics Global (NASDAQ: PRE - Get Free Report) and Neuphoria Therapeutics (NASDAQ: NEUP - Get Free
Company Urges Shareholders to Follow ISS' Recommendation and Vote the WHITE Proxy Card BURLINGTON,
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significa
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the
Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote
Confirms Receipt of Unsolicited Indication of Interest and Director Nominations from Lynx1 Master Fu
BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Tu
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic rev